{
    "name": "ceftazidime/avibactam",
    "comment": "Rx",
    "other_names": [
        "Avycaz"
    ],
    "classes": [
        "Cephalosporins",
        "3rd Generation"
    ],
    "source": "https://reference.medscape.com/drug/avycaz-ceftazidime-avibactam-999985",
    "pregnancy": {
        "common": [
            "There are no adequate and well-controlled studies of ceftazidime/avibactam, ceftazidime, or avibactam in pregnant women",
            "Neither ceftazidime nor avibactam were teratogenic in rats at doses 40 and 9 times the recommended human clinical dose; in the rabbit, at twice the exposure as seen at the human clinical dose, there were no effects on embryofetal development with avibactam",
            "Because animal reproduction studies are not always predictive of human response, this drug should be used in pregnancy only if clearly needed"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Ceftazidime is excreted in human milk in low concentrations",
            "Unknown whether avibactam is excreted into human milk, although avibactam was shown to be excreted in the milk of rats",
            "No information is available on the effects of ceftazidime and avibactam on the breastfed child or on milk production"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Known serious hypersensitivity to avibactam, ceftazidime, or other cephalosporins"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "In clinical trials, cure rates were lower in patients with baseline moderate renal impairment (CrCl 30-50 mL/min) who were treated for cIAI with ceftazidime/avibactam plus metronidazole (45% cure rate) compared with meropenem (74% cure rate); during the clinical trial, the ceftazidime/avibactam dose was 33% lower than what is currently recommended for patients with moderate renal impairment (see Dosage Modifications); follow current dosage adjustment recommendations for renal impairment",
                "Serious and occasionally fatal anaphylactic reactions and serious skin reactions have been reported with beta-lactam antibacterials; caution in patients with history of allergy to cephalosporins, penicillins, or carbapenems; exercise caution if this product is to be given to a penicillin or other beta-lactam-allergic patient; cross sensitivity among beta-lactam antibacterial drugs established; discontinue drug if allergic reaction occurs",
                "Seizures, nonconvulsive status epilepticus, encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with ceftazidime, especially in the setting of renal impairment; adjust dose according to CrCl (see Dosage Modifications)",
                "Confirm suspected bacterial infection when prescribing ceftazidime/avibactam to avoid the risk of developing drug-resistant bacteria; prescribing antibiotics in absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to patient and increases risk of development of drug-resistant bacteria"
            ],
            "specific": [
                {
                    "type": "Clostridium difficile-associated diarrhea",
                    "description": [
                        "Clostridium difficile associated diarrhea (CDAD) has been associated with nearly all systemic antibacterials; severity may range from mild diarrhea to fatal colitis; may occur >2 months following antibacterial use; if CDAD suspected, manage fluid and electrolytes levels and monitor antibacterial treatment for CDAD",
                        "C. difficile produces toxins A and B which contribute to development of CDAD; hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial use; careful medical history necessary because CDAD has been reported tooccur more than 2 months after administration of antibacterial drugs",
                        "If CDAD suspected or confirmed, antibacterial drugs not directed against C. difficile may need to be discontinued; manage fluid and electrolyte levels as appropriate, supplement protein intake, monitor antibacterial treatment of C. difficile, and institute surgical evaluation as clinically indicated"
                    ]
                },
                {
                    "type": "Drug interactions overview",
                    "description": [
                        "Avibactam is an OAT1/OAT3 substrate; probenecid, a potent OAT inhibitor, inhibits OAT uptake of avibactam by 56-70% and potentially decrease the elimination of avibactam when coadministered; therefore, coadministration of ceftazidime/avibactam with probenecid is not recommended",
                        "Ceftazidime administration may result in a false-positive reaction for glucose in the urine with certain methods; glucose tests based on enzymatic glucose oxidase reactions be used"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "cholera vaccine",
            "description": {
                "common": "ceftazidime/avibactam, cholera vaccine. pharmacodynamic antagonism. Avoid or Use Alternate Drug. Avoid coadministration of cholera vaccine with systemic antibiotics since these agents may be active against the vaccine strain. Do not administer cholera vaccine to patients who have received oral or parenteral antibiotics within 14 days prior to vaccination."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "microbiota oral",
            "description": {
                "common": "ceftazidime/avibactam decreases effects of microbiota oral by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Microbiota oral contains bacterial spores. Antibacterial agents may decrease efficacy if coadministered. Complete antibiotic regimens 2-4 days before initiating microbiota oral. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "probenecid",
            "description": {
                "common": "probenecid increases levels of ceftazidime/avibactam by decreasing renal clearance. Use Caution/Monitor. Avoid, coadministration not recommended according to the prescribing information. In vitro, probenecid inhibits uptake of avibactam by OATP1 and OATP3 transporters in the kidney by 56-70%. This may result in decreased renal elimination of avibactam."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "voclosporin",
            "description": {
                "common": "voclosporin, ceftazidime/avibactam.\nEither increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Diarrhea",
            "percent": "8"
        },
        {
            "name": "Nausea",
            "percent": "7"
        },
        {
            "name": "Vomiting",
            "percent": "5"
        },
        {
            "name": "Headache",
            "percent": "3"
        },
        {
            "name": "Dizziness",
            "percent": "2"
        },
        {
            "name": "Abdominal pain",
            "percent": "1"
        },
        {
            "name": "Vomiting",
            "percent": "3"
        },
        {
            "name": "Diarrhea",
            "percent": "3"
        },
        {
            "name": "Rash",
            "percent": "3"
        },
        {
            "name": "Infusion site phlebitis",
            "percent": "3"
        },
        {
            "name": "Diarrhea",
            "percent": "3"
        },
        {
            "name": "Nausea",
            "percent": "3"
        },
        {
            "name": "Constipation",
            "percent": "2"
        },
        {
            "name": "Upper abdominal pain",
            "percent": "1"
        },
        {
            "name": "Nausea",
            "percent": "3"
        },
        {
            "name": "Pruritus",
            "percent": "2"
        },
        {
            "name": "Blood and lymphatic disorders",
            "percent": null
        },
        {
            "name": "Thrombocytopenia",
            "percent": null
        },
        {
            "name": "thrombocytosis",
            "percent": null
        },
        {
            "name": "leukopenia",
            "percent": null
        },
        {
            "name": "General disorders and administration site conditions",
            "percent": null
        },
        {
            "name": "Injection site phlebitis",
            "percent": null
        },
        {
            "name": "Infections and infestations",
            "percent": null
        },
        {
            "name": "Candidiasis",
            "percent": null
        },
        {
            "name": "Investigations",
            "percent": null
        },
        {
            "name": "Increased aspartate aminotransferase",
            "percent": null
        },
        {
            "name": "increased alanine aminotransferase",
            "percent": null
        },
        {
            "name": "increased gamma",
            "percent": null
        },
        {
            "name": "glutamyltransferase",
            "percent": null
        },
        {
            "name": "Metabolism and nutrition disorders",
            "percent": null
        },
        {
            "name": "Hypokalemia",
            "percent": null
        },
        {
            "name": "Nervous system disorders",
            "percent": null
        },
        {
            "name": "Dysgeusia",
            "percent": null
        },
        {
            "name": "Renal and urinary disorders",
            "percent": null
        },
        {
            "name": "Acute kidney injury",
            "percent": null
        },
        {
            "name": "renal impairment",
            "percent": null
        },
        {
            "name": "nephrolithiasis",
            "percent": null
        },
        {
            "name": "Skin and subcutaneous tissue disorders",
            "percent": null
        },
        {
            "name": "Rash",
            "percent": null
        },
        {
            "name": "rash maculopapular",
            "percent": null
        },
        {
            "name": "urticaria",
            "percent": null
        },
        {
            "name": "Psychiatric disorders",
            "percent": null
        },
        {
            "name": "Anxiety",
            "percent": null
        }
    ]
}